The MFDS ensures that generics meet bioequivalence requirements by mandating comparative studies between the generic and the reference drug. These studies must demonstrate that the generic has similar pharmacokinetics, including absorption, distribution, metabolism, and excretion. The results are rigorously evaluated to confirm safety, efficacy, and therapeutic equivalence.
